Dracen Pharmaceuticals announces oral presentation at Festival of...

Presentation explores the benefits of broadly targeting glutamine metabolism in cancer and provides a clinical development update on Dracen’s sirpiglenastat (DRP-104)(PRWeb March 09, 2022)Read the full story at https://www.prweb.com/releases/dracen_pharmaceuticals_announces_oral_presentation_at_festival_of_biologics_world_immunotherapy_congress_2022/prweb18544215.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news